clinical trial · NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines·phase3·recruiting·n = 500
Chronic Lymphocytic LeukemiaSonrotoclaxZanubrutinibAcalabrutinibVenetoclax
brief summary
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
started
Jan 22, 2026
primary completion
Feb 1, 2031
completion
Nov 1, 2031
last updated
Apr 22, 2026
official title
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol